DE3839126A1
(de)
*
|
1988-11-19 |
1990-05-23 |
Hoechst Ag |
Renin-hemmende harnstoffderivate von dipeptiden, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung
|
NZ235234A
(en)
*
|
1989-09-12 |
1992-12-23 |
Hoechst Ag |
Renin-inhibiting amino acid derivatives and pharmaceutical compositions thereof
|
US6313094B1
(en)
|
1990-12-11 |
2001-11-06 |
Japan Energy Corporation |
β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
|
US5554728A
(en)
*
|
1991-07-23 |
1996-09-10 |
Nexstar Pharmaceuticals, Inc. |
Lipid conjugates of therapeutic peptides and protease inhibitors
|
WO1993002674A1
(en)
*
|
1991-08-02 |
1993-02-18 |
Smithkline Beecham Corporation |
Hiv protease inhibitors
|
NZ249789A
(en)
*
|
1992-03-11 |
1997-07-27 |
Narhex Ltd |
Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
|
US5888992A
(en)
*
|
1992-03-11 |
1999-03-30 |
Narhex Limited |
Polar substituted hydrocarbons
|
US6071895A
(en)
*
|
1992-03-11 |
2000-06-06 |
Narhex Limited |
Polar-substituted hydrocarbons
|
DE69333270T2
(de)
|
1992-03-11 |
2004-08-05 |
Narhex Ltd. |
Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
|
US5972990A
(en)
*
|
1992-04-10 |
1999-10-26 |
Brigham And Women's Hospital, Inc. |
Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
|
US5559256A
(en)
*
|
1992-07-20 |
1996-09-24 |
E. R. Squibb & Sons, Inc. |
Aminediol protease inhibitors
|
IL110898A0
(en)
*
|
1993-09-10 |
1994-11-28 |
Narhex Australia Pty Ltd |
Polar-substituted hydrocarbons
|
JPH08277287A
(ja)
*
|
1995-02-09 |
1996-10-22 |
Mitsubishi Chem Corp |
インダゾール類およびその用途
|
US6423689B1
(en)
|
1997-12-22 |
2002-07-23 |
Warner-Lambert Company |
Peptidyl calcium channel blockers
|
CA2382547A1
(en)
*
|
1999-09-21 |
2001-03-29 |
Stephen R. Hanson |
Methods and compositions for treating platelet-related disosders
|
WO2001070672A2
(en)
|
2000-03-23 |
2001-09-27 |
Elan Pharmaceuticals, Inc. |
Compounds and methods to treat alzheimer's disease
|
ES2375268T3
(es)
|
2000-12-14 |
2012-02-28 |
The Brigham And Women's Hospital, Inc. |
Marcadores inflamatorios para la detección y prevención de diabetes mellitus.
|
HUE039881T2
(hu)
|
2002-05-09 |
2019-02-28 |
Brigham & Womens Hospital Inc |
1L1RL-1, mint egy kardiovaszkuláris betegség-marker
|
US7273616B2
(en)
*
|
2002-05-10 |
2007-09-25 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
|
AU2004266705A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
CA2536975A1
(en)
*
|
2003-08-28 |
2005-03-17 |
Nitromed, Inc. |
Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
|
EP1663184A2
(en)
|
2003-08-29 |
2006-06-07 |
The Brigham And Women's Hospital, Inc. |
Hydantoin derivatives as inhibitors of cellular necrosis
|
EP1697746B1
(en)
|
2003-12-05 |
2012-02-22 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
WO2005070006A2
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
US7803838B2
(en)
*
|
2004-06-04 |
2010-09-28 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
CA2624601C
(en)
|
2004-10-06 |
2018-07-03 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
WO2006055542A2
(en)
*
|
2004-11-15 |
2006-05-26 |
Nitromed, Inc. |
Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
|
CA2595579A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
SG175477A1
(en)
*
|
2005-01-31 |
2011-11-28 |
Mylan Lab Inc |
Hydroxylated nebivolol metabolites
|
AU2006336387A1
(en)
*
|
2005-02-16 |
2007-08-02 |
Nicox S.A. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
EP1858863A1
(en)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
EP1861093A2
(en)
*
|
2005-03-09 |
2007-12-05 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
AP2896A
(en)
|
2005-05-31 |
2014-05-31 |
Mylan Lab Inc |
Compositions comprising nebivolol
|
WO2007016677A2
(en)
|
2005-08-02 |
2007-02-08 |
Nitromed, Inc. |
Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
|
US20090054381A1
(en)
*
|
2005-10-04 |
2009-02-26 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
US20080057590A1
(en)
|
2006-06-07 |
2008-03-06 |
Mickey Urdea |
Markers associated with arteriovascular events and methods of use thereof
|
CA2668744C
(en)
|
2006-11-17 |
2015-09-15 |
Queen's University At Kingston |
Compounds and methods for treating protein folding disorders
|
AU2008242764B2
(en)
|
2007-04-18 |
2013-10-24 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US7828840B2
(en)
*
|
2007-11-15 |
2010-11-09 |
Med Institute, Inc. |
Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
|
EP2373317B1
(en)
|
2008-11-25 |
2016-12-14 |
Merck Sharp & Dohme Corp. |
4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
|
AR074425A1
(es)
|
2008-12-05 |
2011-01-19 |
Merck Sharp & Dohme |
Derivados de nitrooxi como antagonistas del receptor de angiotensina ii.
|
MX2011008952A
(es)
|
2009-02-26 |
2011-09-27 |
Merck Sharp & Dohme |
Activadores de guanilato ciclasa solubles.
|
SG182821A1
(en)
|
2010-02-01 |
2012-08-30 |
Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
SG10201502031XA
(en)
|
2010-03-31 |
2015-05-28 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
WO2011146371A1
(en)
|
2010-05-21 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
CN103347385A
(zh)
|
2010-10-29 |
2013-10-09 |
默沙东公司 |
二醇二氮烯鎓类杂环衍生物
|
CN103384661B
(zh)
|
2011-01-20 |
2016-08-10 |
默沙东公司 |
盐皮质激素受体拮抗剂
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
AU2012250059A1
(en)
|
2011-04-26 |
2013-10-10 |
Elexopharm Gmbh |
Aldosterone synthase inhibitors
|
US9272987B2
(en)
|
2011-05-02 |
2016-03-01 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
WO2013066714A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
EP2773206B1
(en)
|
2011-10-31 |
2018-02-21 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
US9265772B2
(en)
|
2012-05-11 |
2016-02-23 |
Reset Therapeutics, Inc. |
Carbazole-containing sulfonamides as cryptochrome modulators
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
EP2879666B1
(en)
|
2012-08-01 |
2020-04-08 |
Tavakoli, Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
WO2014085210A1
(en)
|
2012-11-29 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassium channel
|
WO2014099836A1
(en)
|
2012-12-19 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
US9725452B2
(en)
|
2013-03-15 |
2017-08-08 |
Presidents And Fellows Of Harvard College |
Substituted indoles and pyrroles as RIP kinase inhibitors
|
WO2015088886A1
(en)
|
2013-12-11 |
2015-06-18 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
US9611278B2
(en)
|
2013-12-11 |
2017-04-04 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
US10000484B2
(en)
|
2013-12-18 |
2018-06-19 |
Merck Sharp & Dohme Corp. |
Inhibitors of the renal outer medullary potassim channel
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
US10590485B2
(en)
|
2014-05-29 |
2020-03-17 |
Geneticure Llc |
Therapeutic regimen for hypertension
|
US10011572B2
(en)
|
2014-07-29 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
TN2017000113A1
(en)
|
2014-10-31 |
2018-07-04 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
EP3310782B1
(en)
|
2015-05-28 |
2021-12-01 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
EP3322420B1
(en)
|
2015-07-13 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
US11008313B2
(en)
|
2016-09-20 |
2021-05-18 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as PCSK9 allosteric binders
|
US10947222B2
(en)
|
2016-11-18 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
EP3972589B1
(en)
|
2019-05-22 |
2024-07-03 |
Merck Sharp & Dohme LLC |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
US20220273669A1
(en)
|
2019-05-22 |
2022-09-01 |
Merck Sharp Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
WO2021041770A1
(en)
|
2019-08-30 |
2021-03-04 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
EP4185587A1
(en)
|
2020-07-22 |
2023-05-31 |
JANSSEN Pharmaceutica NV |
Compounds useful as factor xia inhibitors
|
US11845748B2
(en)
|
2021-03-18 |
2023-12-19 |
Janssen Pharmaceutica Nv |
Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
US11919881B2
(en)
|
2021-03-18 |
2024-03-05 |
Janssen Pharmaceutica Nv |
Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
|
US11814364B2
(en)
|
2021-03-18 |
2023-11-14 |
Janssen Pharmaceutica Nv |
Pyridine N-oxide derivatives useful as factor XIa inhibitors
|
US11897880B2
(en)
|
2021-04-30 |
2024-02-13 |
Janssen Pharmaceutica Nv |
7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
|
US11958856B2
(en)
|
2021-07-22 |
2024-04-16 |
Janssen Pharmaceutica Nv |
Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
|
MX2024002146A
(es)
|
2021-08-19 |
2024-03-08 |
Merck Sharp & Dohme Llc |
Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
|